- Home
- LEO vs AVTX Comparison
LEO vs AVTX Comparison
Compare LEO & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LEO | AVTX |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.4M | 328.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | LEO | AVTX |
|---|---|---|
| Price | $6.37 | $13.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $40.57 |
| AVG Volume (30 Days) | 203.1K | ★ 902.6K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $160.00 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $5.67 | $3.39 |
| 52 Week High | $6.55 | $20.72 |
Technical Indicators
Market Signals| Indicator | LEO | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 40.86 |
| Support Level | $6.34 | $13.38 |
| Resistance Level | $6.54 | $19.06 |
| Average True Range (ATR) | 0.08 | 1.33 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 76.60 | 5.64 |
Price Performance
Historical ComparisonAbout LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products include equity and fixed income mutual funds, retail money market funds, government/treasury money market funds, institutional money market funds, and others. The company and its affiliates, as well as others involved in the management, sales, investment activities, business operations, or distribution of the fund, are engaged in businesses and have interests other than those of managing the fund.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.